Haploidentical CD34 cells
Showing 1 - 25 of >10,000
Hematologic Disorders Trial in Aurora (Miltenyi CliniMACS® CD34 Reagent System)
Recruiting
- Hematologic Disorders
- Miltenyi CliniMACS® CD34 Reagent System
-
Aurora, ColoradoUniversity of Colorado
Feb 22, 2022
Myelodysplastic Syndrome (MDS) With Refractory Anemia (RA), Severe Aplastic Anemia (SAA) Trial run by the NHLBI (Umbilical Cord
Completed
- Myelodysplastic Syndrome (MDS) With Refractory Anemia (RA)
- Severe Aplastic Anemia (SAA)
- Umbilical Cord Blood
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Dec 16, 2021
Leukemia, Myelodysplastic Syndrome, Lymphoma Trial in New York (CliniMACS Fractionation system (Arm A), CliniMACS Fractionation
Completed
- Leukemia
- +2 more
- CliniMACS Fractionation system (Arm A)
- +2 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Jul 12, 2022
Benign Tumor, Bone Marrow Transplantation Recipient, Hematopoietic Cell Transplantation Recipient Trial in Portland (Bone Marrow
Available
- Benign Neoplasm
- +3 more
- Bone Marrow Transplantation
- +2 more
-
Portland, OregonOHSU Knight Cancer Institute
Dec 9, 2021
AML, ALL, Lymphoid Malignancies Trial in Birmingham (Infusion of CD34 selected hematopoietic stem cells)
Not yet recruiting
- AML
- +5 more
- Infusion of CD34 selected hematopoietic stem cells
-
Birmingham, AlabamaUniversity of Alabama at Birmingham
Sep 14, 2023
Stem Cell Transplant Complications, Graft Vs Host Disease, Myeloid Leukemia, Acute Trial in Boston (radiation, drug, biological,
Recruiting
- Stem Cell Transplant Complications
- +4 more
- Radiation
- +7 more
-
Boston, MassachusettsDana Farber Cancer Institute
Jan 19, 2023
Sickle Cell Disease Trial in Paris (DREPAGLOBE drug product)
Active, not recruiting
- Sickle Cell Disease
- DREPAGLOBE drug product
-
Paris, FranceDepartment of Biotherapy, Necker-Enfants Malades Hospital
Sep 26, 2022
Chronic Myeloid Leukemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia Trial in Atlanta (G-CSF mobilized CD34+ selected
No longer available
- Chronic Myeloid Leukemia
- +2 more
- G-CSF mobilized CD34+ selected cells for transplantation
-
Atlanta, GeorgiaEmory University/Winship Cancer Institute
Feb 28, 2022
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome Trial in Worldwide (ATIR101, Haploidentical
Completed
- Acute Myeloid Leukemia
- +2 more
- ATIR101
- +3 more
-
Brugge, Belgium
- +10 more
May 17, 2021
Mitochondrial Diseases, Pearson Syndrome Trial in Ramat Gan (MNV-201)
Recruiting
- Mitochondrial Diseases
- Pearson Syndrome
- MNV-201
-
Ramat Gan, IsraelSheba Medical Center
Aug 24, 2023
ß-thalassemia Trial (BD211)
Not yet recruiting
- β-thalassemia
- BD211
- (no location specified)
Mar 15, 2023
Retinitis Pigmentosa Trial in Sacramento (Intravitreal autologous CD34+ cells)
Recruiting
- Retinitis Pigmentosa
- Intravitreal autologous CD34+ cells
-
Sacramento, CaliforniaUniversity of California Davis
Sep 1, 2022
ß-thalassemia Trial in Shanghai (BD211)
Not yet recruiting
- β-thalassemia
- BD211
-
Shanghai, ChinaShanghai Ruijin Hospital
Mar 16, 2023
B-cell Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in Charleston (Cyclophosphamide injection, Fludarabine
Not yet recruiting
- B-cell Non Hodgkin Lymphoma
- Chronic Lymphocytic Leukemia
- Cyclophosphamide injection
- +2 more
-
Charleston, South CarolinaHollings Cancer Center at Medical University of South Carolina
Jan 18, 2023
CD34 + Stem Cells and Biological Markers of Angiogenesis in
Recruiting
- Vasculopathy
- Heart Transplant Failure
- coronary CT angiography
-
Ljubljana, SloveniaAdvanced Heart Failure and Transplantation Center, University Me
Aug 2, 2022
Severe Aplastic Anemia, MDS (Myelodysplastic Syndrome) Trial in Baltimore, Bethesda, Minneapolis (Miltenyi CD34 Reagent System,
Recruiting
- Severe Aplastic Anemia
- MDS (Myelodysplastic Syndrome)
- Miltenyi CD34 Reagent System
- Donor derived G-CSF mobilized PBC
-
Baltimore, Maryland
- +2 more
Jan 25, 2023
Mucopolysaccharidosis II Trial (Autologous CD34+ HSCs transduced ex vivo with CD11B LV encoding human IDS tagged with ApoEII)
Not yet recruiting
- Mucopolysaccharidosis II
- Autologous CD34+ HSCs transduced ex vivo with CD11B LV encoding human IDS tagged with ApoEII
- (no location specified)
Dec 16, 2022
Non-exudative Age-related Macular Degeneration, Diabetic Retinopathy, Retina Vein Occlusion Trial in Sacramento (CD34+ bone
Enrolling by invitation
- Non-exudative Age-related Macular Degeneration
- +4 more
- CD34+ bone marrow stem cells intravitreal
-
Sacramento, CaliforniaUniversity of California Davis
Aug 8, 2022
Hiv Trial in Philadelphia (Autologous CD4 T-Cells)
Completed
- Hiv
- Autologous CD4 T-Cells
-
Philadelphia, PennsylvaniaUniversity of Pennsylvania
Nov 13, 2022
Sickle Cell Disease Trial in United States (CD34 selected T-cell depleted allogeneic SCT)
Active, not recruiting
- Sickle Cell Disease
- CD34 selected T-cell depleted allogeneic SCT
-
Los Angeles, California
- +5 more
Sep 27, 2022
Adenosine Deaminase Severe Combined Immune Deficiency Trial (A cryopreserved formulation of autologous mPB CD34+ hematopoietic
Not yet recruiting
- Adenosine Deaminase Severe Combined Immune Deficiency
- A cryopreserved formulation of autologous mPB CD34+ hematopoietic stem and progenitor cells transduced ex vivo with the EFS-ADA lentiviral vector encoding the human ADA enzyme
- (no location specified)
Jun 20, 2022
Sickle Cell Disease Trial in Birmingham, Palo Alto, Saint Louis (GPH101 Drug Product)
Active, not recruiting
- Sickle Cell Disease
- GPH101 Drug Product
-
Birmingham, Alabama
- +2 more
Jan 5, 2023
Sickle Cell Disease Trial in Saint Louis (Motixafortide, Natalizumab, Leukapheresis)
Not yet recruiting
- Sickle Cell Disease
- Motixafortide
- +2 more
-
Saint Louis, MissouriWashington University School of Medicine
Nov 8, 2022
Sickle Cell-thalassemia Disease, Thalassemia Trial in Washington (peripheral blood stem cell graft that are CD34+ selected)
Active, not recruiting
- Sickle Cell-thalassemia Disease
- Thalassemia
- peripheral blood stem cell graft that are CD34+ selected
-
Washington, District of ColumbiaChildrens National Medical Center
Jul 15, 2021